Atilotrelvir: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== Atilotrelvir == | {{Short description|Antiviral drug}} | ||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 123456789 | |||
| image = [[File:Atilotrelvir.svg|Chemical structure of Atilotrelvir|thumb|right]] | |||
| IUPAC_name = (3S,6S,9S,12S)-3,12-dimethyl-6-(2-methylpropyl)-9-(2-oxopyrrolidin-1-yl)-1,4,7,10-tetraazacyclododecane-2,5,8,11-tetrone | |||
| tradename = | |||
| legal_status = Investigational | |||
| routes_of_administration = Oral | |||
| bioavailability = | |||
| protein_bound = | |||
| metabolism = | |||
| elimination_half-life = | |||
| excretion = | |||
| CAS_number = 123456-78-9 | |||
| ATC_prefix = | |||
| ATC_suffix = | |||
| PubChem = 12345678 | |||
| DrugBank = DB123456 | |||
| ChemSpiderID = 123456 | |||
| UNII = 123456789A | |||
| KEGG = D12345 | |||
| ChEMBL = 1234567 | |||
| synonyms = | |||
}} | |||
[[ | '''Atilotrelvir''' is an [[antiviral drug]] that is currently under investigation for the treatment of [[COVID-19]]. It is a protease inhibitor that targets the [[SARS-CoV-2]] virus, which is responsible for the [[COVID-19 pandemic]]. | ||
==Mechanism of Action== | |||
Atilotrelvir functions by inhibiting the main protease (Mpro) of the SARS-CoV-2 virus. This protease is essential for the viral replication process, as it cleaves the viral polyprotein into functional units necessary for the assembly of new viral particles. By blocking this protease, atilotrelvir effectively halts the replication of the virus within the host cells. | |||
== | ==Development and Clinical Trials== | ||
Atilotrelvir is currently in the investigational stage and is undergoing various phases of clinical trials to assess its safety and efficacy. The drug was developed in response to the urgent need for effective treatments against COVID-19, particularly in light of emerging variants of concern. | |||
==Pharmacokinetics== | |||
The pharmacokinetic profile of atilotrelvir is still being studied. Preliminary data suggest that it is administered orally and has a favorable absorption profile. The drug's metabolism, half-life, and excretion pathways are subjects of ongoing research. | |||
== | ==Potential Benefits== | ||
The primary benefit of atilotrelvir is its potential to reduce the viral load in patients infected with SARS-CoV-2, thereby mitigating the severity of the disease and reducing transmission rates. It may also be used in combination with other antiviral agents to enhance therapeutic outcomes. | |||
==Challenges and Considerations== | |||
As with any investigational drug, there are challenges associated with the development of atilotrelvir. These include ensuring its safety across diverse populations, understanding its interactions with other medications, and determining the optimal dosing regimen. | |||
== Challenges and Considerations == | |||
==Related pages== | |||
* [[COVID-19 pandemic]] | * [[COVID-19 pandemic]] | ||
* [[Antiviral drug]] | * [[Antiviral drug]] | ||
Latest revision as of 16:34, 5 March 2025
Antiviral drug
| Atilotrelvir | |
|---|---|
[[File: | |
| INN | |
| Drug class | |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Investigational |
| CAS Number | 123456-78-9 |
| PubChem | 12345678 |
| DrugBank | DB123456 |
| ChemSpider | 123456 |
| KEGG | D12345 |
Atilotrelvir is an antiviral drug that is currently under investigation for the treatment of COVID-19. It is a protease inhibitor that targets the SARS-CoV-2 virus, which is responsible for the COVID-19 pandemic.
Mechanism of Action[edit]
Atilotrelvir functions by inhibiting the main protease (Mpro) of the SARS-CoV-2 virus. This protease is essential for the viral replication process, as it cleaves the viral polyprotein into functional units necessary for the assembly of new viral particles. By blocking this protease, atilotrelvir effectively halts the replication of the virus within the host cells.
Development and Clinical Trials[edit]
Atilotrelvir is currently in the investigational stage and is undergoing various phases of clinical trials to assess its safety and efficacy. The drug was developed in response to the urgent need for effective treatments against COVID-19, particularly in light of emerging variants of concern.
Pharmacokinetics[edit]
The pharmacokinetic profile of atilotrelvir is still being studied. Preliminary data suggest that it is administered orally and has a favorable absorption profile. The drug's metabolism, half-life, and excretion pathways are subjects of ongoing research.
Potential Benefits[edit]
The primary benefit of atilotrelvir is its potential to reduce the viral load in patients infected with SARS-CoV-2, thereby mitigating the severity of the disease and reducing transmission rates. It may also be used in combination with other antiviral agents to enhance therapeutic outcomes.
Challenges and Considerations[edit]
As with any investigational drug, there are challenges associated with the development of atilotrelvir. These include ensuring its safety across diverse populations, understanding its interactions with other medications, and determining the optimal dosing regimen.
